Impact of uptake time on image quality of [ Ga]Ga-PSMA-11 PET/CT.

Background: With the introduction of prostate specific membrane antigen (PSMA) PET/CT, the detection rate of prostate cancer metastases has improved significantly, both for primary staging and for biochemical recurrence. EANM/SNMMI guidelines recommend a 60 min time interval between [ Ga]Ga-PSMA administration and acquisition.

Purpose: This study evaluates the possibility of a shorter time interval by investigating the dynamic change in image quality measures.

Tolerability of concurrent external beam radiotherapy and [Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment naïve patients, phase I study (PROQURE-I trial).

Background: Prostate cancer patients with locoregional lymph node disease at diagnosis (N1M0) still have a limited prognosis despite the improvements provided by aggressive curative intent multimodal locoregional external beam radiation therapy (EBRT) with systemic androgen deprivation therapy (ADT). Although some patients can be cured and the majority of patients have a long survival, the 5-year biochemical failure rate is currently 29-47%. [Lu]Lu-PSMA-617 has shown impressive clinical and biochemical responses with low toxicity in salvage setting in metastatic castration-resistant prostate cancer.

[PSMA PET, an important addition in prostate cancer diagnostics].

PSMA PET/CT is a diagnostic technique for patients with prostate cancer. It makes use of a radioligand that specifically binds to 'prostate specific membrane antigen' (PSMA), expressed by the prostate cancer cells. PSMA PET has proven to be highly effective in prostate cancer diagnostics in both primary staging and re-staging.

Baseline Imaging Derived Predictive Factors of Response Following [Lu]Lu-PSMA-617 Therapy in Salvage Metastatic Castration-Resistant Prostate Cancer: A Lesion- and Patient-Based Analysis.

Earlier studies have mostly identified pre-therapeutic clinical and laboratory parameters for the prediction of treatment response to [177Lu]Lu-PSMA-617 in metastatic castration resistant prostate cancer patients (mCRPC). The current study investigated whether imaging-derived factors on baseline [68Ga]Ga-PSMA-11 PET/CT can potentially predict the response after two cycles of [177Lu]Lu-PSMA-617 treatment, in a lesion- and patient-based analysis in men with mCRPC. Included patients had histologically proven mCRPC and a [68Ga]Ga-PSMA-11 PET/CT before and after two cycles of [177Lu]Lu-PSMA-617 treatment.

Competition ('Steal' Phenomenon) between [Ga]Ga-PSMA-11 Uptake in Prostate Tumor Tissue Versus Healthy Tissue.

We aimed to clarify whether a steal 'phenomenon' exists by investigating if uptake of 'prostate specific membrane antigen' (PSMA) in prostate tumor tissue correlates with the uptake in healthy tissue. Patients with prostate cancer referred for a [Ga]Ga-PSMA-11 PET/CT were identified retrospectively. Semi-automated quantitative image analysis was performed; fractional healthy tissue [Ga]Ga-PSMA-11 uptake volume (HT-PSMA (SUV*cm)) in the lacrimal, submandibular, and parotid glands, and kidneys, and the fractional total lesion [Ga]Ga-PSMA-11 uptake volume (TL-PSMA (SUV*cm)) of prostate cancer were used.

Management of Radiologically Indeterminate Magnetic Resonance Imaging Signals in Men at Risk of Prostate Cancer.

Background: Multiparametric magnetic resonance imaging (mp-MRI) is becoming an increasingly important diagnostic tool for prostate cancer. So far there has been little focus on management for indeterminate mp-MRI results.

Objective: To describe outcomes for a cohort of men rated as having an indeterminate mp-MRI result.